Table 1.
Modality | Role | Imaging features of HCC |
Sensitivity |
Specificity |
Advantages | Disadvantages | |||
All size | ≤ 20 mm | All size | ≤ 20 mm | ||||||
US | B-mode US | Screening and surveillance | Nodules with altered echogenicity (hypo- or hyperechoic) and abnormal portal venous and/or arterial blood flow compared with background liver. | 51%-67% | 26%-49% | 80%-100% | 67%-80% | 1. Real-time, less expensive, no ionizing radiation. 2. CEUS Allows real-time continuous imaging and characterization of the dynamic washin of contrast agents. 3. CEUS Can help resolve indeterminate vascular shunts detected by CT or MRI. | 1. Requires recognized expertise to perform good examinations. 2. Sensitive to inter- and intraobserver variabilities. 3. Limited application in obese patients and patients with very cirrhotic heterogeneous livers. 4. US is less accurate compared with CT and MRI for HCC diagnosis. 5. CEUS may demonstrate deteriorated performance for deep, subdiaphragmatic, multiple and treated lesions. |
CEUS | Focal liver lesion characterization, rapid diagnosis | Hyperenhancement in the hepatic arterial phase and wash-out appearance in the portal venous and/or delayed phases. | 80%-94% | 55%-76% | 82%-98% | 80%-98% | |||
CT | Diagnostic | Hyperenhancement in the hepatic arterial phase and wash-out appearance in the portal venous and/or delayed phases. | 63%-76% | 63%-70% | 87%-98% | 89%-93% | 1. Widely available and well validated worldwide. 2. Enables full cross-sectional evaluation of the liver and can provide important staging information. 3. Demonstrates high specificity for HCC diagnosis. | 1. Ionizing radiation exposure. 2. Requires application intravenous contrast agents. 3. Less sensitive for early and small lesions. | |
MRI | All | Diagnostic | Hyperenhancement in the hepatic arterial phase and wash-out appearance in the portal venous and/or delayed phases. | 77%-90% | 68%-85% | 84%-97% | 88%-95% | 1. No ionizing radiation exposure; 2. Widely available and well validated worldwide; 3. Enables full cross-sectional evaluation of the liver and can provide important staging information; 4. Demonstrate high specificity for HCC diagnosis; 5. Better depiction of tumor intrinsic characteristics than CT. | 1. More Sensitive to motion and susceptibility artifact. 2. Requires injection of potentially nephrotoxic contrast agents. 3. More time-consuming than CT or US. 4. Limited sensitivity for early and small lesions. |
Gadolinium-enhanced MRI | 67%-82% | 57%-75% | 68%-95% | 86%-94% | |||||
Gadoxetate-enhanced MRI | Arterial phase hyperenhancement, portal venous phase wash-out appearance and hepatobiliary phase hypointensity. | 79%-93% | 90%-93% | 90%-97% | 87%-91% | 1. Permits evaluation of hepatocyte functions. 2. Very sensitive for early and small lesions. 3. Hepatobiliary phase signal intensity is well correlated with HCC histologic grade. 4. Can help differentiate early HCCs from cirrhosis-associated benign nodules. | 1. Prolonged examination time and increased cost. 2. Less available and validated than CT or conventional MR. 3. Some HCCs can appear iso- or even hyperintense on hepatobiliary phase images. 4. Hepatobiliary phase hypointensity may be appreciated in a wide spectrum of diseases with both benign and malignant entities. 5. Delayed phase, which can better depict washout appearance, is absent. |
US: Ultrasound; CEUS: Contrast-enhanced ultrasound; CT: Computed tomography; MRI: Magnetic res-onance imaging; HCC: Hepatocellular carcinoma.